Project Grant R21CA296742
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$419K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $131,910 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate treatment strategies and clinical outcomes of histotripsy, a non-thermal ablation technique, for complete ablation of osteosarcoma in canine models. The key objectives are to: 1) investigate the treatment parameters and strategies needed for complete ablation of ex vivo canine...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $210,789 to Texas A&M University System Health Science Center to conduct research on a DKK-1 targeting antisense therapy for osteosarcoma. The research aims to characterize the effects of a canine version of the DKK-1 inhibiting antisense therapy (cDKKMO) on canine osteosarcoma cell lines and patient-derived xenografts, as well as test the therapy's ability to inhibit tumor...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,985 to Colorado State University to conduct research on a novel immunotherapy targeting local and systemic immunity for the treatment of ocular surface squamous neoplasia (OSSN), a progressive ocular cancer. The research aims to elucidate the immunological mechanisms underlying the antitumor activity of the liposomal-TLR agonist immunotherapy (LTAC) in an equine spontaneous OSSN...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $672,844 supports research to determine the effectiveness of a monoclonal antibody (B10G5) in activating natural killer (NK) cells and reshaping the tumor microenvironment to improve adoptive NK cell therapy for canine soft tissue sarcomas. The research, conducted by Northwestern University, aims to: 1) evaluate the safe and effective dose of B10G5 in activating endogenous NK cells...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award to Northwestern University, spanning 2025-2029, has two key objectives: Determine whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary...
Oregon State University will receive $500,000 from the National Science Foundation under the Technology, Innovation, and Partnerships program to develop cancer therapeutics for dogs. Specifically, the university will construct and test prototype dual epitope-binding therapeutic antibodies targeting the canine PD-1 protein for the treatment of canine cancers. Researchers will design various single domain antibody configurations and select an optimal construct using recombinant DNA methods and...
This $641,936.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to harness neutrophils, a type of white blood cell, and engineer them with chimeric antigen receptors (CARs) to treat glioblastoma, an aggressive form of brain cancer. The primary awardee, Purdue University, will develop and optimize neutrophil-specific CAR constructs, evaluate the antitumor activities of CAR-neutrophils combined with radiation or CAR-T cell therapy...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...